Ge Long Hui·2025-12-03 10:03Core Viewpoint - Fosun Pharma has received approval from the National Medical Products Administration for clinical trials of FXS887, an innovative oral small molecule drug aimed at treating advanced malignant solid tumors [1] Group 1: Clinical Development - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., plans to conduct Phase I clinical trials for FXS887 in China once conditions are met [1] - FXS887 specifically inhibits ATR kinase activity, intervening in cell cycle regulation and DNA damage repair pathways to suppress malignant proliferation of tumor cells [1] Group 2: Preclinical Research - Preclinical studies have shown that FXS887 exhibits good anti-tumor activity across various tumor models, with a low off-target risk and good safety profile [1] - As of October 2025, the cumulative R&D investment for FXS887 is approximately RMB 44 million (unaudited) [1] Group 3: Market Context - As of the announcement date, there are no approved small molecule inhibitors targeting the same pathway as FXS887, either as monotherapy or in combination therapy, globally [1]